免疫调节剂治疗鼻部炎症性疾病专家共识(2023,深圳)
作者:
作者单位:

作者简介:

通讯作者:

基金项目:

国家自然科学基金杰出青年基金(81725004);国家自然科学基金(81870706,81670901,81873689,81873690,81870700,82071014,82171104,82171119,82171120,82101201,82260219,82071018);上海市科委项目(20MC920200,19XD4010000);上海市促进市级医院临床技能与临床创新能力三年行动计划项目(SHDC2020CR4090);上海申康医学发展中心临床科技创新项目(SHDC12019X07);上海市卫生健康委先进适宜技术推广项目(2019SY071);四川省科技厅重点研发项目(2021YFS0036);四川省人社厅留学人员回国科技活动项目择优资助(川人社函〔2020〕291号);成都市科技局重点产业研发支撑计划(2021-YF05-00473-SN);福建省自然科学基金面上项目(2020J01981);福建省卫生教育联合攻关计划项目(2019-wj-25);广东省自然科学基金面上项目(2022A1515012617,2022A1515012394);深圳市科技计划项目(JCYJ20210324121413037)。


Expert consensus on immunomodulatory drugs for nasal inflammatory diseases (2023,Shenzhen)
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    鼻部炎症性疾病临床主要包括变应性鼻炎(AR)、非变应性鼻炎(NAR)和慢性鼻窦炎(CRS),其发病机制尚未完全阐明,涉及遗传学、免疫调节、炎症介质、环境因素、微生物群状态等多方面,传统药物治疗后部分患者症状仍无法缓解或出现不必要的副作用,且容易反复发作或呈慢性持续状态,因其发病多与免疫失衡相关,免疫调节是一个有效的治疗方案。近年来,免疫调节剂的品种和应用越来越广泛,主要包括化学合成制剂、生物制剂、人和动物免疫系统的产物、中药及其制剂等。但免疫调节剂治疗鼻部炎症疾病缺乏高水平的循证医学证据,使用尚不规范,因此,我们特组织该领域有经验的中青年鼻科专家,基于临床经验和循证医学证据制定了免疫调节剂治疗鼻部炎症性疾病专家共识,本共识从鼻部炎症性疾病发病机制角度出发,系统总结了鼻炎及CRS常用免疫调节剂的免疫作用机制、临床研究证据、适应证、用法用量及注意事项等,以供临床医生在选择和应用免疫调节剂时参考。

    Abstract:

    The clinical entity of nasal inflammatory diseases mainly includes allergic rhinitis, non-allergic rhinitis and chronic rhinosinusitis. The pathogenesis has not been fully clarified, involving genetics, immune regulation, inflammatory mediators, environmental factors, microbial community status, and other aspects. Conventional drug treatment may fail to relieve symptoms or even cause side effect in some patients.And the patients are prone to recurrent the disease or be in chronic persistent state. Considering its pathogenesis mostly related to immune imbalance, immune regulation is an effective treatment plan. Recently, the variety and application of immunomodulatory drugs have become more and more extensive, including chemically synthesized molecules, biological agents, products of human and animal immune systems, and traditional Chinese medicine. However, the application of immunomodulatory drugs in the treatment of nasal inflammatory diseases is not standardized due to the lack of high-level evidence-based medical evidences. Therefore, we intentionally organized young and middle-aged nasal experts with experience in this field to develop an expert consensus on immunomodulatory drugs for the treatment of nasal inflammatory diseases based on clinical experience and evidence-based medical evidence. This consensus systematically summarizes the immune mechanisms,clinical research evidence, indications, usage and dosage, as well as precautions of immunomodulatory drugs for rhinitis and chronic rhinosinusitis, so as to provide a reference for clinical selection and application of immunomodulatory drugs.

    参考文献
    相似文献
    引证文献
引用本文

杨贵,廖芸,张维天,余少卿,杨钦泰,王向东,陈建军,孟娟,孟粹达,许元腾,孙悦奇,许成利,王英,杨玉成,刘锋,孙娜,赵可庆,唐隽,杨艳莉,陆美萍,邱前辉,王洪田,喻国冻,安云芳,左可军,石照辉,叶惠平,孙斌,孙亚男,曾明,许昱,巴罗,张天虹,顾瑜蓉,王天生,叶菁,谢志海,洪海裕,魏欣,徐睿,李勇,李华斌.免疫调节剂治疗鼻部炎症性疾病专家共识(2023,深圳)[J].中国耳鼻咽喉颅底外科杂志,2023,29(1):1-14

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2023-01-18
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-03-03
温馨提示

本刊唯一投稿网址:www.xyosbs.com
唯一办公邮箱:xyent@126.com
编辑部联系电话:0731-84327210,84327469
本刊从未委托任何单位、个人及其他网站代理征稿及办理其他业务联系,谨防上当受骗!

关闭